ReShape Lifesciences, Inc. Aktie News

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Therapeutics, Inc. (“Vyome”), a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced that it has closed the previously disclosed transaction with ReShape Lifesciences Inc. (Nasdaq: RSLS). The post-merger company will trade at the open of tradi...

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced that The Nasdaq Stock Market has approved its listing upon completion of the Company's previously announced merger with ReShape Lifesciences (Nasdaq: RSLS), which is ex...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced its post-closing Board of Directors, expected to take control of the ReShape Lifesciences (NASDAQ: RSLS) public entity on Friday, August 15, 2025, which will be renamed Vyome Hol...

IRVINE, Calif.--(BUSINESS WIRE)---- $HIND--ReShape Lifesciences® (Nasdaq: RSLS) announced today that its shareholders have approved all of the proposals necessary to complete the previously announced merger with Vyome Therapeutics, which is expected to be effective for the commencement of trading on Friday, August 15, 2025. The shares of common stock of the combined company are expected to comm...

Partial Adjournment for Proposal 2, Asset Sale Proposal, and Proposal 3, Charter Amendment Proposal; All Other Proposals Required for Merger Were Approved

Company to Host Pre-Eminent Lap-Band® Surgeon Advocates For a Three-Day Seminar, August 1-3, 2025 Company to Host Pre-Eminent Lap-Band® Surgeon Advocates For a Three-Day Seminar, August 1-3, 2025

Board of Directors Unanimously Recommend Approving Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys

Patent Enhances and Broadens the Company's Intellectual Property Portfolio Around a Swallowable and Degradable Intragastric Device Patent Enhances and Broadens the Company's Intellectual Property Portfolio Around a Swallowable and Degradable Intragastric Device